Juan Jesús
Gómez-Reino Carnota
Hospital Clinic Barcelona
Barcelona, EspañaPublicacións en colaboración con investigadores/as de Hospital Clinic Barcelona (20)
2019
-
Evaluation of 12 GWAS-drawn SNPs as biomarkers of rheumatoid arthritis response to TNF inhibitors. A potential SNP association with response to etanercept
PLoS ONE, Vol. 14, Núm. 2
-
Factors associated with long-term retention of treatment with golimumab in a real-world setting: an analysis of the Spanish BIOBADASER registry
Rheumatology International, Vol. 39, Núm. 3, pp. 509-515
-
Objectives and methodology of BIOBADASER phase III
Reumatologia Clinica, Vol. 15, Núm. 4, pp. 229-236
2018
-
Persistence and adverse events of biological treatment in adult patients with juvenile idiopathic arthritis: Results from BIOBADASER
Arthritis Research and Therapy, Vol. 20, Núm. 1
-
Validation study of genetic biomarkers of response to TNF inhibitors in rheumatoid arthritis
PLoS ONE, Vol. 13, Núm. 5
2017
-
Rituximab retreatment in rheumatoid arthritis in a real-life cohort: Data from the CERERRA collaboration
Journal of Rheumatology, Vol. 44, Núm. 2, pp. 162-169
2016
-
Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis
Pharmacogenomics Journal, Vol. 16, Núm. 2, pp. 137-140
2015
-
Actualización 2014 del Documento de Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas en la artritis reumatoide
Reumatologia Clinica, Vol. 11, Núm. 5, pp. 279-294
-
Eficacia y seguridad de golimumab añadido a fármacos antirreumáticos modificadores de la enfermedad en artritis reumatoide. Resultados del estudio GO-MORE en España
Reumatologia Clinica, Vol. 11, Núm. 3, pp. 144-150
-
FCGR polymorphisms in the treatment of rheumatoid arthritis with Fc-containing TNF inhibitors
Pharmacogenomics, Vol. 16, Núm. 4, pp. 333-345
-
Rheumatoid arthritis response to treatment across IgG1 allotype - anti-TNF incompatibility: A case-only study
Arthritis Research and Therapy, Vol. 17, Núm. 1
2014
-
Health-related quality of life in psoriatic arthritis patients in Spain
Reumatologia Clinica, Vol. 10, Núm. 1, pp. 25-31
-
Lack of replication of interactions between polymorphisms in rheumatoid arthritis susceptibility: Case-control study
Arthritis Research and Therapy, Vol. 16, Núm. 1
2013
-
Cutaneous adverse events during treatment of chronic inflammatory rheumatic conditions with tumor necrosis factor antagonists: Study using the spanish registry of adverse events of biological therapies in rheumatic diseases
Arthritis Care and Research, Vol. 65, Núm. 12, pp. 2024-2031
-
El uso de abatacept en artritis reumatoide: Revisión de la evidencia y recomendaciones
Reumatologia Clinica, Vol. 9, Núm. 1, pp. 5-17
2012
-
Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: The MIRAR Study
Annals of the Rheumatic Diseases, Vol. 71, Núm. 11, pp. 1861-1864
2010
-
Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists
Annals of the Rheumatic Diseases, Vol. 69, Núm. 10, pp. 1751-1755
2009
-
Analysis of TNFAIP3, a feedback inhibitor of nuclear factor-κB and the neighbor intergenic 6q23 region in rheumatoid arthritis susceptibility
Arthritis Research and Therapy, Vol. 11, Núm. 2
2008
-
Association of interferon regulatory factor 5 haplotypes, similar to that found in systemic lupus erythematosus, in a large subgroup of patients with rheumatoid arthritis
Arthritis and Rheumatism, Vol. 58, Núm. 5, pp. 1264-1274
2006
-
Switching TNF antagonists in patients with chronic arthritis: An observational study of 488 patients over a four-year period
Arthritis Research and Therapy, Vol. 8, Núm. 1